About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« $$$ in Applicants' Pockets! | Main | Patent Profile: U.S. Patent No. 7,125,706 to Introgen Therapeutics, Inc. for Purified Adenoviral Compositions »

November 24, 2006

Pfizer and Teva Announce $70M Settlement

    By Christopher P. Singer --

Pfizer Pfizer and Teva on November 21, 2006 announced that the companies reached an agreement that resolves litigation surrounding the drugs idarubicin and azithromycin, as well as issues relating to epirubicin.  The resolution includes full releases between the parties and directs a payment as large as $70 million from Teva to Pfizer.  The dispute between subsidiary companies Pharmacia (Pfizer) and Sicor (Teva) centered on Sicor’s sale of a generic form of the injectible anti-cancer drug idarubicin HCl (Pharmacia's IDAMYCIN PFS).  Pfizer also filed suit against Teva for its sale of a generic form of the antibiotic azithromycin (Pfizer’s Zithromax).  Under terms of the agreement Teva will continue its sale of generic idarubicin and azithromycin, and has a 2007 option to sell a generic version of epirubicin (Pfizer's ELLENCE), which is used in adjuvant therapy in patients that show evidence of axillary node tumor Teva involvement following resection of primary breast cancer.  Pfizer’s patent coverage of epirubicin is set to expire in August 2007.

Compounds

Posted at 05:47 PM in Patent Litigation |

Comments

The comments to this entry are closed.

September 2024

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

Categories

Archives

More...